Likes Subject
$BCTX $15 Price Target smallcapvoice 04/27/23 12:15 PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured smallcapvoice 01/30/23 2:45 PM
Strange stock, but I've loved having it the Onree 01/20/23 11:19 AM
Yep, I'm still here. She's getting ready to chenzo11 06/15/22 3:23 PM
Under $4 by end of month Nickwvt 04/14/22 12:19 PM
BriaCell Therapeutics Price Target Announced at $25.00/Share by crudeoil24 04/13/22 8:14 AM
BriaCell Reports Received FDA Fast Track Approval For crudeoil24 04/13/22 8:10 AM
I'm still here....wait til you see what happens chenzo11 04/09/22 12:12 AM
Closed above resistance of $10.50....We dance on Monday chenzo11 11/19/21 4:41 PM
$BCTX BriaCell is an immuno-oncology focused biotechnology company lucky__stock 11/05/21 10:44 AM
$BCTX announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. lucky__stock 11/05/21 10:22 AM
$BCTX has added Pioneering Immunologist and Cancer Immunotherapy lucky__stock 11/05/21 9:58 AM
Easy Money for more $ZOM shares $BCTX thanks EyalCap 10/03/21 1:45 PM
(Nasdaq: BCTX, BCTXW) (TSX-V: BCT) CEO highlights key StockHighAlert- 09/23/21 11:49 AM
BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX-V:BCT) News StockHighAlert- 08/23/21 10:58 AM
BCTX Nebuchadnezzar 08/13/21 12:42 AM
MarketsandMarkets 4th Annual Next Gen Immuno-Oncology Virtual Congress-US ThurstonHowell 06/29/21 2:00 PM ThurstonHowell 06/29/21 1:56 PM ThurstonHowell 06/16/21 3:04 PM ThurstonHowell 06/16/21 3:03 PM
Terrible timing though. Absolutely killed any momentum. retireat40 06/03/21 8:31 PM
Yeah that wasn't bad news with private offering HabibiFresh 06/03/21 11:47 AM
Hopefully the squeeze alone will take it over jwakstock 06/03/21 11:23 AM
Yes, Nasdaq halted it again, Those MMS timetomakemoney 06/03/21 10:56 AM
My hunch the halt is because there are cbrad10480 06/03/21 10:52 AM
What the Hell, there was a market for timetomakemoney 06/03/21 10:51 AM
PPS could go either way... My hunch timetomakemoney 06/03/21 10:43 AM
I've never seen a halt for news and cbrad10480 06/03/21 10:41 AM
We thinking buyout with this halt? Wouldn't halt HabibiFresh 06/03/21 10:38 AM
Yeah real curious was about to happen HabibiFresh 06/03/21 10:37 AM
100% resolution for eye-bulging tumors I love it HabibiFresh 06/03/21 10:37 AM
Over an hour and BCTX is still halted. timetomakemoney 06/03/21 10:35 AM
Yall seen a halt before big news before? HabibiFresh 06/03/21 10:19 AM
Has to be more than that as it's Penny chatter 06/03/21 10:11 AM
Offering news out...$5.26 with exercise at $6.17 it appears. retireat40 06/03/21 9:46 AM
News Out! Public offering 5.2 million shares and warrants. timetomakemoney 06/03/21 9:43 AM
Company: BriaCell Therapeutics Corp. ANTADOG 06/03/21 9:17 AM
Look again INFINITI 06/03/21 9:15 AM
Bid now 10 dollar, what i see, ANT ANTADOG 06/03/21 9:14 AM
Yes. Windsortrader519 06/03/21 8:56 AM
correction bid is now 8,50, fyi ANT ANTADOG 06/03/21 8:44 AM
i hope this one gets attention from the ANTADOG 06/03/21 8:43 AM
There is no bid or ask INFINITI 06/03/21 8:41 AM
you mean why it stays 6,50 pm with ANTADOG 06/03/21 8:19 AM
Did they halt this INFINITI 06/03/21 8:11 AM
massive day here 146 million volume and counting Nebuchadnezzar 06/02/21 6:42 PM
* * $BCTX Video Chart 06-02-2021 * * ClayTrader 06/02/21 4:47 PM
Raised 27M - Market Cap 42M - with aristotelisonassis 06/02/21 4:43 PM
Nope...shorts are killing this. retireat40 06/02/21 4:02 PM
Great retireat40 06/02/21 4:01 PM
Likes Subject

04/27/23 12:15 PM
04/14/22 12:19 PM
09/23/21 11:49 AM
08/13/21 12:42 AM
06/03/21 11:47 AM
06/03/21 11:23 AM
06/03/21 10:56 AM
06/03/21 10:52 AM
06/03/21 10:51 AM
06/03/21 10:43 AM
06/03/21 10:41 AM
06/03/21 10:38 AM
06/03/21 10:37 AM
06/03/21 10:37 AM
06/03/21 10:35 AM
06/03/21 10:19 AM
Penny chatter
06/03/21 10:11 AM
06/03/21 9:17 AM
06/03/21 9:15 AM
06/03/21 9:14 AM
06/03/21 8:56 AM
06/03/21 8:44 AM
06/03/21 8:43 AM
06/03/21 8:41 AM
06/03/21 8:19 AM
06/03/21 8:11 AM
06/02/21 6:42 PM
06/02/21 4:47 PM
06/02/21 4:43 PM
06/02/21 4:02 PM
06/02/21 4:01 PM

BriaCell Therapeutics Corp. (BCTX)

Posts (Today)
Posts (Total)

About BriaCell

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based vaccine technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.

In a preliminary Phase I clinical study in metastatic (i.e., Stage IV) breast cancer patients who had failed multiple treatments, Bria-IMT™ treatment significantly reduced the tumor size, without serious side effects. Importantly, the tumor regression was observed in other sites including the lung and even the brain -a difficult site. Impressively, the median lifespan of the patients was substantially longer than that of the comparable trials.

At our laboratory facility in Berkeley, CA, we are planning to expand our pipeline of oncology immunotherapy candidates using our proprietary technology platform.

Using the clinical data from the patients from the clinical studies, we are working to identify the molecular fingerprint of the patients for which the vaccine would be highly effective, and are planning to develop diagnostic testing products to identify this group. By directing the drug to the top-responders, we expect this approach to increase the likelihood of clinical trial success of Bria-IMT™ -to bring hope to thousands of cancer patients with few-to-no treatment options.

The company is currently recruiting its Phase I/IIa trial to further test Bria-IMT™ safety and activity in metastatic breast cancer patients. BriaCell maintains global rights for Bria-IMT™.

Phase I/IIa Clinical Study of Bria-IMT™ in Advanced Breast Cancer

BriaCell is currently recruiting patients to evaluate the safety and activity of Bria-IMT™ in an additional Phase I/IIa study in 25-40 metastatic breast cancer patients who have failed at least one course of treatment.

For the details of the trial, please visit For the details of the trial, please visit

Roll-Over Combination Therapy Study

FDA has approved the roll-over combination study of Bria-IMT™ with pembrolizumab (Keytruda; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy; manufactured by Bristol-Myers Squibb Company) for patients previously treated with BriaVax™ from the ongoing Phase I/IIa Clinical Trial in Advanced Breast Cancer. The study is available for patents on the SV-BR-1-GM Phase I/IIa study who develop progressive disease. These patients will be eligible to roll-over into combination therapy with Keytruda or Yervoy, depending on the type of breast cancer they have.

More information on the roll-over combination study of Bria-IMT™ with either ipilimumab or pembrolizumab will be available on (

KEYTRUDA® (pembrolizumab)

Manufactured by Merck & Co., Inc., KEYTRUDA® (pembrolizumab) is a prescription medicine that may treat certain cancers by working with the immune system. It has been approved for the treatment of a number of cancer indications excluding breast cancer.

For more information on pembrolizumab, please see:

About YERVOY® (ipilimumab)

Manufactured by Bristol-Myers Squibb Company, YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable). It is a monoclonal antibody that works to activate the immune system and enabling them to recognize and destroy cancer cells.

For more informations on Ipilimumab, please see:


Clinical Development Timeline – Breast Cancer

Most Liked Posts
(Last 30 Days)
New Post